Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy.
暂无分享,去创建一个
P. Massip | C. Pasquier | J. Izopet | S. Raymond | P. Delobel | B. Marchou | K. Sauné | N. Jeanne | A. Saliou | M. Cazabat
[1] P. Massip,et al. Characterization of CXCR4-using HIV-1 during primary infection by ultra-deep pyrosequencing. , 2013, The Journal of antimicrobial chemotherapy.
[2] J. Mullins,et al. An Increasing Proportion of Monotypic HIV-1 DNA Sequences during Antiretroviral Treatment Suggests Proliferation of HIV-Infected Cells , 2012, Journal of Virology.
[3] T. Dallman,et al. Performance comparison of benchtop high-throughput sequencing platforms , 2012, Nature Biotechnology.
[4] M. Nei,et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.
[5] Ron Milo,et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy , 2011, Nature.
[6] Thomas Lengauer,et al. Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis , 2011, BMC Medical Informatics Decis. Mak..
[7] V. Calvez,et al. Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism , 2011, Antimicrobial Agents and Chemotherapy.
[8] V. Calvez,et al. Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years , 2011, AIDS.
[9] J. Izopet,et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists , 2010 .
[10] V. Calvez,et al. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. , 2010, The Journal of antimicrobial chemotherapy.
[11] P. Massip,et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[12] G. Angarano,et al. Co‐receptor switch during HAART is independent of virological success , 2009, Journal of medical virology.
[13] V. Calvez,et al. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART , 2007, AIDS.
[14] R. Cheynier,et al. Naïve T-Cell Depletion Related to Infection by X4 Human Immunodeficiency Virus Type 1 in Poor Immunological Responders to Highly Active Antiretroviral Therapy , 2006, Journal of Virology.
[15] Christophe Pasquier,et al. R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.
[16] P. Massip,et al. Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. , 2002, Virology.
[17] Ziheng Yang,et al. Statistical methods for detecting molecular adaptation , 2000, Trends in Ecology & Evolution.
[18] B. Clotet,et al. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. , 1999, Virology.
[19] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[20] E. Poveda,et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. , 2010, The Journal of antimicrobial chemotherapy.
[21] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.